Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 5
2004 6
2005 9
2006 11
2007 10
2008 11
2009 7
2010 10
2011 9
2012 5
2013 7
2014 5
2015 12
2016 11
2017 12
2018 17
2019 19
2020 11
2021 18
2022 27
2023 24
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Results by year

Filters applied: . Clear all
Page 1
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Lambertini M, et al. JAMA. 2024 Jan 2;331(1):49-59. doi: 10.1001/jama.2023.25463. JAMA. 2024. PMID: 38059899
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. Del Mastro L, et al. Among authors: fabi a. Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10. Lancet Oncol. 2022. PMID: 36370716 Clinical Trial.
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Among authors: fabi a. Cancer Treat Rev. 2024 Feb;123:102672. doi: 10.1016/j.ctrv.2023.102672. Epub 2023 Dec 14. Cancer Treat Rev. 2024. PMID: 38118302 Free article. Review.
Oligometastatic Breast Cancer: How to Manage It?
Barberi V, Pietragalla A, Franceschini G, Marazzi F, Paris I, Cognetti F, Masetti R, Scambia G, Fabi A. Barberi V, et al. Among authors: fabi a. J Pers Med. 2021 Jun 9;11(6):532. doi: 10.3390/jpm11060532. J Pers Med. 2021. PMID: 34207648 Free PMC article. Review.
Supportive care in neurooncology.
Pace A, Metro G, Fabi A. Pace A, et al. Among authors: fabi a. Curr Opin Oncol. 2010 Nov;22(6):621-6. doi: 10.1097/CCO.0b013e32833e078c. Curr Opin Oncol. 2010. PMID: 20706120 Review.
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Garufi G, Carbognin L, Arcanà C, Parola S, Ventriglia A, Doronzo A, Garutti M, Orlandi A, Palazzo A, Fabi A, Bria E, Tortora G, Arpino G, Giuliano M, Del Mastro L, De Laurentiis M, Puglisi F. Garufi G, et al. Among authors: fabi a. Cancer Treat Rev. 2022 Nov;110:102454. doi: 10.1016/j.ctrv.2022.102454. Epub 2022 Aug 11. Cancer Treat Rev. 2022. PMID: 35987149 Review.
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.
Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, Molinelli C, Adamo V, Bianchini G, Biganzoli L, Curigliano G, De Laurentiis M, Fabi A, Frassoldati A, Gennari A, Marchiò C, Perrone F, Viale G, Zamagni C, Zambelli A, Del Mastro L, De Placido S, Guarneri V, Marchetti P, Puglisi F. Garutti M, et al. Among authors: fabi a. Cancers (Basel). 2022 Apr 9;14(8):1898. doi: 10.3390/cancers14081898. Cancers (Basel). 2022. PMID: 35454806 Free PMC article. Review.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Botticelli A, et al. Among authors: fabi a. Oncologist. 2023 Nov 23:oyad308. doi: 10.1093/oncolo/oyad308. Online ahead of print. Oncologist. 2023. PMID: 37995313 Free article.
229 results